Tissue penetration of antimicrobials: Difference between revisions

From IDWiki
No edit summary
No edit summary
Line 10: Line 10:
! colspan="7" |Antibiotics: β-Lactams
! colspan="7" |Antibiotics: β-Lactams
|-
|-
| rowspan="2" |Penicillins
| rowspan="3" |Penicillins
|β-lactamase inhibitors
|β-lactamase inhibitors
|
|
| style="text-align:center" |
| style="text-align:center" |–
|
|
|
|
Line 23: Line 23:
|
|
|
|
| style="text-align:center" |
| style="text-align:center" |–
|-
|-
|[[piperacillin-tazobactam]]
| rowspan="4" |Cephalosporins
|
|
|
| +†
|
|-
| rowspan="5" |Cephalosporins
|first-generation cephalosporins
|first-generation cephalosporins
|
|
| style="text-align:center" |
| style="text-align:center" |–
|
|
|
|
| style="text-align:center" |
| style="text-align:center" |–
|-
|-
|second-generation cephalosporins
|second-generation cephalosporins
|
|
| style="text-align:center" |
| style="text-align:center" |–
|
|
|
|-
|third-generation cephalosporins
|
|
|
|
|
| +†
|
|
|-
|-
Line 57: Line 71:
|[[cephamycins]]
|[[cephamycins]]
|
|
| style="text-align:center" |
| style="text-align:center" |–
|
|
|
|
Line 67: Line 81:
|
|
|
|
| style="text-align:center" |
| style="text-align:center" |–
|-
|-
|Carbapenems
|Carbapenems
Line 85: Line 99:
|
|
|
|
| style="text-align:center" |
| style="text-align:center" |–
|-
|-
|Chloramphenicol
|Chloramphenicol
Line 98: Line 112:
|
|
|
|
| style="text-align:center" | –?
| style="text-align:center" |–?
|
|
| style="text-align:center" | +
| style="text-align:center" | +
Line 106: Line 120:
|[[clindamycin]]
|[[clindamycin]]
|
|
| style="text-align:center" |
| style="text-align:center" |–
|
|
|
|
Line 114: Line 128:
|[[macrolides]]
|[[macrolides]]
|
|
| style="text-align:center" |
| style="text-align:center" |–
|
|
| style="text-align:center" | +
| style="text-align:center" | +
Line 121: Line 135:
|Nitrofurans
|Nitrofurans
|[[nitrofurantoin]]
|[[nitrofurantoin]]
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |
| style="text-align:center" |–
|-
|-
|Nitroimidazoles
|Nitroimidazoles
Line 148: Line 162:
|
|
|
|
| style="text-align:center" |
| style="text-align:center" |–
|
|
|-
|-
Line 154: Line 168:
|[[tetracyclines]]
|[[tetracyclines]]
|
|
| style="text-align:center" |
| style="text-align:center" |–
|
|
| style="text-align:center" | +
| style="text-align:center" | +
Line 176: Line 190:
| style="text-align:center" | +
| style="text-align:center" | +
|}
|}

* † if inflammation present

[[Category:Antimicrobials]]
[[Category:Antimicrobials]]

Revision as of 16:23, 24 August 2020

Class Antimicrobial Blood CNS Urine Prostate Necrotic
Antibiotics: β-Lactams
Penicillins β-lactamase inhibitors
ampicillin +
piperacillin-tazobactam +†
Cephalosporins first-generation cephalosporins
second-generation cephalosporins
third-generation cephalosporins +†
cefepime +
ceftazidime + +
Cephamycins cephamycins
cefoxitin
Carbapenems imipenem +
Antibiotics: Non-β-Lactams
Aminoglycosides
Chloramphenicol chloramphenicol +
Fluoroquinolones –? + +
Lincosamides clindamycin +
Macrolides macrolides +
Nitrofurans nitrofurantoin +
Nitroimidazoles metronidazole +
Rifamycins rifampin +
Sulfonamides sulfamethoxazole
Tetracyclines tetracyclines +
doxycycline +
Antifungals
Azoles fluconazole +
  • † if inflammation present

References

  1. ^  Tomasz Jodlowski, Charles R Ashby, Sarath G Nath. Doxycycline for ESBL-E Cystitis. Clinical Infectious Diseases. 2020. doi:10.1093/cid/ciaa1898.
  2. a b c d e f g h i  Timothy Felton, Peter F. Troke, William W. Hope. Tissue Penetration of Antifungal Agents. Clinical Microbiology Reviews. 2014;27(1):68-88. doi:10.1128/cmr.00046-13.
  3. ^ nau2010pe 
  4. ^  Cornelia B. Landersdorfer, Jürgen B. Bulitta, Martina Kinzig, Ulrike Holzgrabe, Fritz Sörgel. Penetration of Antibacterials into Bone. Clinical Pharmacokinetics. 2009;48(2):89-124. doi:10.2165/00003088-200948020-00002.
  5. a b c d e f g h i j k l m n o p q r  L. Brockhaus, D. Goldblum, L. Eggenschwiler, S. Zimmerli, C. Marzolini. Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics. Clinical Microbiology and Infection. 2019;25(11):1364-1369. doi:10.1016/j.cmi.2019.01.017.
  6. a b  Takashi Suzuki, Toshihiko Uno, Guangming Chen, Yuichi Ohashi. Ocular distribution of intravenously administered micafungin in rabbits. Journal of Infection and Chemotherapy. 2008;14(3):204-207. doi:10.1007/s10156-008-0612-5.
  7. ^  Tony H. Huynh, Mark W. Johnson, Grant M. Comer, Douglas N. Fish. Vitreous Penetration of Orally Administered Valacyclovir. American Journal of Ophthalmology. 2008;145(4):682-686. doi:10.1016/j.ajo.2007.11.016.
  8. ^  Luis F. López-Cortés, R. Ruiz-Valderas, M. J. Lucero-Muñoz, E. Cordero, M. T. Pastor-Ramos, J. Marquez. Intravitreal, Retinal, and Central Nervous System Foscarnet Concentrations after Rapid Intravenous Administration to Rabbits. Antimicrobial Agents and Chemotherapy. 2000;44(3):756-759. doi:10.1128/aac.44.3.756-759.2000.